| Literature DB >> 22065594 |
Morie A Gertz1, Francis K Buadi, Suzanne R Hayman, David Dingli, Angela Dispenzieri, Philip R Greipp, Shaji K Kumar, Martha Q Lacy, John A Lust, Nelson Leung, S Vincent Rajkumar, Stephen J Russell, Steven R Zeldenrust, Joseph R Mikhael, Vivek Roy, Robert A Kyle.
Abstract
IgD monoclonal gammopathies are uncommon. They are seen rarely as a monoclonal gammopathy of undetermined significance and are present in 1%-2% of patients with multiple myeloma. In light-chain amyloidosis, IgD monoclonal proteins are found in ap-proximately 1% of patients. When an IgD monoclonal protein is found, amyloidosis is often omitted from the differential diagnosis. In the present study, we reviewed the natural history of IgD-associated amyloidosis among 53 patients seen over 41 years. The distribution of clinical syndromes suggests that these patients have a lower frequency of renal and cardiac involvement. The overall survival of these patients does not appear to be different from that of patients who have light-chain amyloidosis associated with another monoclonal protein.Entities:
Mesh:
Substances:
Year: 2011 PMID: 22065594 DOI: 10.1182/blood-2011-06-358895
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113